Cevec Pharmaceuticals GmbH. (10/14/15). "Press Release: Cevec Strengthens Team to Execute Rapid Growth Strategy. Dr. Nico Scheer Appointed as Vice President Business Development Glycoproteins". Cologne.

	Organisation	Cevec Pharmaceuticals GmbH
	Group	Cevec (Group)
	Organisation 2	Taconic Biosciences GmbH
	Group	Taconic (Group)
	Product	CAP®GT cell line
	Product 2	CAP®Go expression platform (Cevec)
	Person	Scheer, Nico (Cevec 201511– VP Business Development Glycoproteins before Taconic Biosciences/Artemis)
	Person 2	Tintrup, Hartmut (Cevec 201511– VP Business Developm Gene Therapy/Viruses before CBO joined 2010 before amaxa US)

> Dr. Hartmut Tintrup appointed as Vice President Business Development Gene Therapy and Viruses

> Headcount increased by 40% since May 2015

CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced the expansion and reorganization of its management team.

Dr. Nico Scheer will join the Company as Vice President Business Development Glycoproteins as of November 1, 2015. Dr. Scheer will be responsible for CEVEC’s growth strategy in the Company’s CAP®Go activities. Dr. Hartmut Tintrup, currently Chief Business Officer, moves to the position of Vice President Business Development Gene Therapy and Viruses in which he will be responsible for the growth of CEVEC’s CAP®GT business. Both will be reporting to CEO Frank Ubags.

Frank Ubags, Chief Executive Officer of CEVEC Pharmaceuticals GmbH, commented, ”Following our focus on glycoproteins and gene therapy vectors in May 2015 and the subsequent successful co-operations, we have increased our overall headcount by 40% and attracted competent, talented people in the scientific, quality assurance and regulatory business fields. We are experiencing an exponentially increasing demand for our CAP®Go portfolio in the field of glycoproteins and for our CAP®GT technology for the industrial scale production of gene therapy vectors. With this strengthening and restructuring of the management team, we are now well placed to further accelerate the growth of our Company.”

“It’s an exciting time to join CEVEC, as the Company is poised to take advantage of significant growth and expansion opportunities to build market leadership in the production of tailor-made recombinant glycoproteins,” added Dr. Nico Scheer. “I am delighted to get the opportunity to identify and form alliances that unlock the full potential of CEVEC’s unique CAP Go Technology.”

Prior to joining CEVEC, Dr. Scheer served in different leading management positions within Artemis Pharmaceuticals GmbH, TaconicArtemis GmbH and Taconic Biosciences GmbH – most recently as Director Business Development and Head of tADMET portfolio. Dr. Scheer adds more than 10 years of experience in business development, portfolio and project management, plus licensing and partnering activities in the life science industry as well as a strong scientific background in drug metabolism, molecular biology, and in vitro technologies. He holds a PhD in Molecular Developmental Biology and a PMI certified Project Management Professional (PMP).

About CEVEC:

Privately held CEVEC, based in Cologne, Germany, is an expert for the production of tailor-made recombinant glyco-proteins and gene therapy vectors. The Company’s core technologies, CAP®Go and CAP®GT are based on a unique human cellular expression system.

The CAP®Go expression platform comprises a portfolio of glyco-optimized human suspension cell lines for tailor-made glycosylation of recombinant proteins. The cells are highly efficient for the production of a broad range of difficult to express glyco-proteins and provide authentic human post-translational modifications. CAP®Go has proven to enhance the activity, stability and serum half-life of several candidate proteins.

The CAP®GT expression platform provides a fully scalable, regulatory endorsed production system for gene therapy vectors. CAP®GT cells grow to high cell densities and show a broad viral propagation spectrum including lentivirus (LV), adenovirus (AV) and adeno-associated virus (AAV). Furthermore, CAP®GT enables easier scale-up and reduced production costs when compared to adherent cell culture systems.

Research collaborations with international pharmaceutical and biotechnology partners followed by licensing agreements for the technology form one revenue base for CEVEC. In addition, the Company provides contract manufacturing for the GMP production in CAP®Go and CAP®GT cells.

Contact:

CEVEC Pharmaceuticals GmbH
Frank Ubags
Chief Executive Officer
T.:+49 221 46020800
E.: ubags@cevec.com

MC Services AG
Anne Hennecke
Public Relations
T.: +49 211 52925222
E.: anne.hennecke@mc-services.eu

Record changed: 2017-04-02

Top News

Upcoming Events

Bio Regions & Life Sciences Clusters

Business Parks & Science Centres

Associations

Partners

Cevec Pharmaceuticals GmbH. (10/14/15). "Press Release: Cevec Strengthens Team to Execute Rapid Growth Strategy. Dr. Nico Scheer Appointed as Vice President Business Development Glycoproteins". Cologne.

More documents for Cevec (Group)